Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki
Dr. Kariuki brings a wealth of experience in ADCs, across corporate strategy, finance and operations Advancement of Pheon’s differentiated ADC pipeline, accelerating first program, PHN-010, into clinical development this year London UK, 10 September 2024 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, […]